Avoiding FDA Warning Letters: How Clinical Investigators Can Partner with IRBs to Stay Compliant

This article delves into the FDA’s issuance of 61 warning letters over the past five years due to regulatory failures that risk participant safety and research credibility. This educational initiative highlights common compliance pitfalls and offers practical strategies for clinical investigators to strengthen oversight and maintain adherence with regulatory standards. This was written for CITI Program's blog.